Antin, Cinven, CVC, KKR and Permira bid to buy unit of Spain's Rovi, Expansion reports

-4.32%

-0.51%

-1.07%

-1.69%

KKR & Co. L.P. KKR	136.60	-4.32%
Dow Jones Industrial Average DJI	48458.05	-0.51%
S&P 500 index SPX	6827.41	-1.07%
NASDAQ IXIC	23195.17	-1.69%

MADRID, June 26 (Reuters) - Investment funds Antin ANTIN.PA, Cinven, CVC CVC.AS, KKR KKR.N and Permira have filed offers to buy Spanish pharmaceutical company Rovi's ROVI.MC third-party manufacturing business, newspaper Expansion reported on Wednesday citing unidentified market sources.

The five firms filed non-binding bids on June 13 and are now in the middle of a due diligence process for binding offers, the newspaper reported.

Rovi said in March it had hired Lazard as an adviser for a potential sale of the unit which has produced COVID vaccines on behalf of Moderna, among other drugs.

The unit is estimated to be worth about 3.5 billion euros ($3.75 billion), Expansion said.

Spokespeople for Rovi, Cinven and KKR declined to comment, while Antin, CVC and Permira did not immediately respond to requests for comment.

($1 = 0.9344 euros)

(Reporting by Inti Landauro; editing by Jason Neely)

((Inti.Landauro@thomsonreuters.com;))

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.